Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (348)	9/2/1998 4:52:00 PM
From: mauser96	Read Replies (2) \| Respond to of 645

This is a live vaccine, delivered through a nasal spray to the target location, the nasal mucosa. The patient will then become infected by this non pathogenic influenza that shares enough antigens with the pathogenic (disease causing) strains that the patient will then become immune to both. One can easily see the need for very precise manufacturing processes to make sure the virus stays alive but isn't contaminated by some other nasty organism. If it was a dead virus the whole dose unit could be simply sterilized, but this isn't possible with a live vaccine. The FDA is going to be very picky. It's also the nature of live vaccines which result in an infection that a very few people with low resistance or maybe some unknown genetic problem will get sick from it. On the other hand they have the potential for conferring life long immunity.